An Act to amend the Code of Virginia by adding a section numbered 38.2-3407.18:1, relating to health insurance; requirements for certain opioid antagonists.
HB795 requires most health insurance policies, subscription contracts, and health maintenance organization plans in Virginia to cover at least one opioid antagonist used for overdose reversal, such as naloxone, when dispensed under an oral, written, or standing order from a prescriber. The bill also requires that at least one covered opioid antagonist be placed on the lowest cost tier of the plan’s prescription drug formulary, which is intended to reduce out-of-pocket costs for patients.
The bill further prohibits insurers from imposing prior authorization or step therapy requirements on this coverage, meaning enrollees should be able to access the covered opioid antagonist without first trying other drugs or obtaining extra approval. The mandate applies to policies and plans delivered, issued for delivery, or renewed in Virginia on and after January 1, 2027, with exclusions for certain limited policies, short-term travel coverage, Medicare-related coverage, and similar governmental plans. It also provides that if the required benefit is already included in the Commonwealth’s essential health benefits benchmark plan, the mandate will not apply in the individual and small group markets for that portion of coverage.
HB795 adds a new section, § 38.2-3407.18:1, to the Code of Virginia and expands state insurance coverage requirements for opioid overdose reversal medications. It affects insurers, health service corporations, and health maintenance organizations by mandating coverage and favorable formulary placement for at least one opioid antagonist, while limiting utilization management tools such as prior authorization and step therapy. The law is prospective, applying to new, delivered, or renewed plans beginning January 1, 2027, and includes carve-outs for certain exempt policy types and for coverage already required through the essential health benefits benchmark plan.
The available record shows no committee transcript or recorded vote data, so there is no documented debate summary or roll-call pattern to assess. Based on the enacted text, the bill appears to reflect a public health-oriented approach aimed at improving access to overdose-reversal medication and reducing cost barriers. The absence of recorded opposition or amendment discussion in the provided materials suggests no visible controversy in the available record, though the policy itself is the kind that can draw attention from insurers because of coverage and formulary requirements.
The main policy tension in HB795 is between expanding access to opioid antagonists and limiting insurer cost-control tools. Insurers and health plans may view the lowest-tier formulary requirement and the ban on prior authorization and step therapy as constraints on utilization management and pricing flexibility, while supporters would likely emphasize affordability and rapid access in overdose emergencies. Another potential point of contention is the scope of the mandate, including which plans are exempt and how the essential health benefits benchmark interaction affects individual and small group markets.